Allogeneic bone marrow transplantation in patients with lymphoma relapsing after autologous marrow transplantation

H. C. Schouten, J. O. Armitage, L. W. Klassen, W. P. Vaughan, P. J. Bierman, D. Weisenburger, A. Kessinger

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

Two patients who underwent autologous bone marrow transplantation for recurrent non-Hodgkin's lymphoma relapsed at 46 and 28 days after the transplant. Both patients had an HLA-identical sibling and were treated with high-dose chemotherapy and allogeneic marrow transplantation. One patient is now 24 months after the allogeneic transplant without evidence of disease. The second patient died on day 7 with interstitial pneumonia. We conclude that high-dose therapy and allogeneic bone marrow transplantation after failure of autologous transplantation for non-Hodgkin's lymphoma is feasible and should be considered in young patients with HLA-identical siblings.

Original languageEnglish (US)
Pages (from-to)119-121
Number of pages3
JournalBone marrow transplantation
Volume4
Issue number1
StatePublished - Jan 1 1989

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Allogeneic bone marrow transplantation in patients with lymphoma relapsing after autologous marrow transplantation'. Together they form a unique fingerprint.

  • Cite this